Esaxerenone Improves Microalbuminuria in Type 2 Diabetes
In a phase 2 study of patients with early diabetic nephropathy, esaxerenone decreased microalbuminuria in a dose-dependent manner over 12 weeks compared with placebo.
Hyperkalemia
HYPERKALEMIA
Preoperative Potassium Predicts Hyperkalemia Post-Parathyroidectomy
In a study of hemodialysis patients, pre-operative potassium higher than 3.9 mmol/L correlated with greater risk for hyperkalemia after parathyroidectomy.
Sodium Zirconium Cyclosilicate Effectively Treats Hyperkalemia in HD
In the DIALIZE trial, 41.2% of hemodialysis patients taking sodium zirconium cyclosilicate maintained normal potassium levels during the long interdialytic interval compared with just 1% receiving placebo.
Researchers Identify Factors Associated With Hyperkalemia in CKD
In a study of chronic kidney disease patients not on dialysis, hyperkalemia developed in more women than men.
Preoperative Hyperkalemia Predicts Worse Outcomes After Cardiac Surgery
Hyperkalemia in patients undergoing cardiac surgery is associated with increases risks for postoperative death, cerebrovascular accidents, and need for dialysis.
Study: Dietary Potassium May Not Increase Hyperkalemia Risk in CKD
In a small study on nondialysis CKD patients, daily potassium intake was not associated with hyperkalemia (serum potassium level above 5 mEqL) in patients with chronic kidney disease.
Sodium Polystyrene Sulfonate Tied to Serious GI Events
In a large, population-based study, patients prescribed sodium polystyrene sulfonate had a nearly 2-fold higher risk of adverse GI events within 30 days of initial prescription.
Could Potassium-Restricted Diets Come to an End?
Hyperkalemia, defined as a serum potassium level above 5.3 mmol/L, develops in many patients with chronic kidney disease (CKD). The abnormality can precipitate serious adverse outcomes, including dysrhythmias and sudden cardiac death, so patients with elevated blood potassium levels may be referred to emergency departments or urgent care facilities for immediate therapy. As a result,…
Potassium Binder May Enable Optimal RAASi Use in CKD
In a study, 87% of hyperkalemic patients on renin-angiotensin-aldosterone system inhibitor (RAASi) therapy were able to continue or increase their RAASi doses while concurrently taking sodium zirconium cyclosilicate.
Hyperkalemia Drug May Help CKD Patients Stay on Spironolactone for Resistant Hypertension
It is challenging for CKD patients to stay on spironolactone therapy because it can increase the risk of hyperkalemia, according to researchers.
Want to read more?
Please login or register first to view this content.
Next post in Secondary Hyperparathyroidism
